Subchronic copper exposure induces parkinsonism in rats: Neuromodulatory potential of curcumin
Objective: We aim herein to assess the effect of subchronic Cu-intoxication (0.125%) for 6 weeks on the dopaminergic, serotonergic and astroglial systems together with behavioral…Chinese patients with Wilson disease and the treatments: exampled with Unithiol (DMPS) intravenous infusion
Objective: The authors performed a retrospective analysis about effects and side-effects for a series of 136 Chinese patients with Wilson disease, treated by Unithiol (DMPS)…Neurologic Wilson’s Disease: Case Series on a Diagnostic and Therapeutic Emergency
Objective: To present two cases of Neurologic Wilson's Disease with two different clinical picture. To review the the important diagnostics and tests in clinching the…Neurological worsening in patients undergoing treatment for Wilson disease: Frequency, causes and outcomes.
Objective: To study the pattern of neurological worsening (NW) in patients undergoing treatment for Wilson disease (WD). Background: WD is an inherited disorder of copper…Disappearance of the clinical and imaging manifestations in Wilson’s disease after controlled therapy with tetrathiomolybdate and zinc
Objective: To present a case with Wilson’s disease (WD) whose neurological and imaging alterations disappeared after ammonium tetrathiomolybdate (AT) and zinc acetate (Zn) controlled therapy. …Curcumin I protect against copper induced neurobehavioral features of Parkinson’s disease in rat
Objective: evaluate the impact of acute Cu intoxication (10 mg/kg B.W. i.p) for 3 days on the dopaminergic system and locomotor performance, together with the…WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study
Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…Clinical and imaging deterioration of a mild case of Wilson’s disease after chelation therapy
Objective: To present a case of a mild wilson disease with neuropsychiatric features which showed clinical and also imaging deteriotation five months after the chelation…Iron accumulation in a Wilson disease patient: Longitudinal 7T MRI and transcranial sonography study
Objective: To investigate longitudinal changes in clinical symptoms, 7T MRI and transcranial sonography (TCS) during chelating treatment in a Wilson disease (WD) patient. Background: Pathophysiological…An ongoing phase 2, multi-centre, open-label, study of WTX101 in Wilson disease patients – Early observations
Objective: The aim of this ongoing study is to evaluate the efficacy and safety of WTX101 in newly diagnosed Wilson Disease patients. Background: WTX101 (bis-choline…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.